GSTM1 and stroke disorder: Similarly, the Trial to Reduce cardiovascular Events with Aranesp Therapy reported that the use of darbepoetin-α (achieved Hb of 13.0 g/dL) did not reduce the risk of overall mortality or cardiovascular events but rather was associated with an increased risk of stroke as compared to the placebo arm treated with rescue darbepoetin-α at an Hb < 9.0 g/dL [9].